Posted 10/16/2023, 11:12:11 AM
Novo Nordisk to Acquire Hypertension Drug Ocedurenone from KBP Biosciences for up to $1.3 Billion
- Novo Nordisk acquiring hypertension drug ocedurenone from KBP Biosciences for up to $1.3 billion
- Deal aligns with Novo's strategy to expand from diabetes into other chronic diseases
- Ocedurenone is an oral drug in phase 3 trial for uncontrolled hypertension and kidney disease
- Acquisition expected to close by end of 2022, no impact to 2023 profit outlook
- Ocedurenone could have applications in cardiovascular and kidney diseases beyond hypertension
